Industry Trends

What pharma needs to do to keep up with the rise in value-based care.

A Q&A with Egon Zehnder’s Sergio Della Zassa about what biopharma executives and search firms are looking for in terms of table stakes skill sets and “unicorn” experiences from top talent in the field.

A Q&A with Professor Frances Frei of the Harvard Business School, who discusses how leaders create the conditions for organizations and individuals to thrive by designing for excellence in operations, strategy, and culture.

A Harvard Business School Healthcare Alumni Association Q&A with Dorie Clark, Instructor of Executive Education at the Columbia Business School.

Partnership expected to utilize Walgreens’ pharmacies as recruitment and trial sites for a clinical study regarding obesity, weight issues, and type 2 diabetes, mainly in historically underrepresented groups.

A Harvard Business School Healthcare Alumni Association Q&A with Matt Wolf, president of Biopharma Services at Cencora.

Healthcare customers and patients are facing more avenues to receive misinformation about drugs than ever before.

Webinar Date/Time: Thursday, May 23, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

A Harvard Business School Healthcare Alumni Association Q&A with Louis Kassa, CEO of the Pennsylvania Biotechnology Center.

Collaboration aims to advance the development of treatments for multiple neurodegenerative conditions, including amyotrophic lateral sclerosis.

Webinar Date/Time: Thursday, May 9, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Webinar Date/Time: Wednesday, May 15th, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

A Q&A with Dr. Zeynep Ton, professor at the MIT Sloan School of Management.

Mills is working in leadership in two roles, one of which puts her on the forefront of the genomic medicine movement.

Marquez discusses the results of a recent survey about how elements of the industry are reacting to a post remote-work world.

Prescribers cite ways to alleviate systemic threats to their ability to serve.

Deal includes the novel treatment CDR132L, which is currently in Phase II clinical trials for heart failure.

The commitment to advancing the fields of oncology and nuclear medicine is not just about adopting new technologies, but also about embracing a more profound change in how care is delivered.

Acquisition is highlighted by eneboparatide, Amolyt’s Phase III peptide for hypoparathyroidism with a novel mechanism of action.

Although research on cannabinoids is now allowed in a growing number of countries, there are still a number of restrictions and corresponding licenses and permits required to work with these chemicals.

A look at pharma and biotech financing, M&A, and stock market performance in 2023—and where developments may head next as company executives continue to navigate stormy but perhaps stabilizing waters in the months ahead.

Webinar Date/Time: Tue, Apr 23, 2024 1:00 PM EDT

Matt Abrahams, a Lecturer in Organizational Behavior at Stanford University’s Graduate School of Business, discusses the importance for job seekers of investing time on qualitative skills, such as communications.

Results indicate that many people aged 50 to 80 years who take aspirin to prevent heart attacks and strokes don’t actually need to.

Results of a study conducted by the National Institutes of Health indicate that the Paxlovid prevented a substantial number of hospitalizations associated with COVID-19.

Planning for a post-recession scenario is essential, ensuring companies are prepared to scale up when funding permits.

Webinar Date/Time: Thu, Mar 28, 2024 2:00 PM EDT

The FDA granted accelerated approval to Elahere in November 2022 for adults with folate receptor-alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Entrenched and emerging hurdles alike are challenging manufacturer pricing and access strategies.

Key steps in relationship-building beyond just treatment options.